Proteomics International Laboratories Limited advised that it is in the closing stages of finalising the detailed terms of its Exclusive Licence Agreement with Sonic Healthcare USA for use of the Company's PromarkerD predictive test for diabetic kidney disease in the United States. The parties signed a binding and exclusive letter of intent in August to enter into an Exclusive Licence Agreement for the PromarkerD predictive test. The Company will update the market once the Exclusive Licence Agreement has been signed.